CA2589987A1 - Methode pour traiter une secretion cholinergique influencee - Google Patents

Methode pour traiter une secretion cholinergique influencee

Info

Publication number: CA2589987A1
Authority: CA; Canada
Prior art keywords: treating; botulinum toxin; secretions; cholinergic; cholinergic influenced
Prior art date: 1993-12-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA002589987A

Other languages

English (en)

Other versions

CA2589987C (fr

Inventor

Michael W. Grayston

Judith M. Leon

Steven R. Carlson

K. Roger Aoki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-28

Filing date

1994-12-16

Publication date

1995-07-06

1994-12-16 Application filed by Individual filed Critical Individual

1994-12-16 Priority claimed from CA002300766A external-priority patent/CA2300766C/fr

1995-07-06 Publication of CA2589987A1 publication Critical patent/CA2589987A1/fr

2008-05-20 Application granted granted Critical

2008-05-20 Publication of CA2589987C publication Critical patent/CA2589987C/fr

2014-12-16 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000028327 secretion Effects 0.000 title abstract 3
230000001713 cholinergic effect Effects 0.000 title abstract 2
108030001720 Bontoxilysin Proteins 0.000 abstract 2
229940053031 botulinum toxin Drugs 0.000 abstract 2
206010023644 Lacrimation increased Diseases 0.000 abstract 1
208000007101 Muscle Cramp Diseases 0.000 abstract 1
208000029578 Muscle disease Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
210000002565 arteriole Anatomy 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
210000000232 gallbladder Anatomy 0.000 abstract 1
210000005095 gastrointestinal system Anatomy 0.000 abstract 1
230000004317 lacrimation Effects 0.000 abstract 1
210000003097 mucus Anatomy 0.000 abstract 1
230000004118 muscle contraction Effects 0.000 abstract 1
210000000664 rectum Anatomy 0.000 abstract 1
210000002460 smooth muscle Anatomy 0.000 abstract 1
210000005070 sphincter Anatomy 0.000 abstract 1
230000035900 sweating Effects 0.000 abstract 1
230000002485 urinary effect Effects 0.000 abstract 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002589987A 1993-12-28 1994-12-16 Methode pour traiter une secretion cholinergique influencee Expired - Fee Related CA2589987C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17399693A	1993-12-28	1993-12-28
US08/173,996		1993-12-28
CA002300766A CA2300766C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002300766A Division CA2300766C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee

Publications (2)

Publication Number	Publication Date
CA2589987A1 true CA2589987A1 (fr)	1995-07-06
CA2589987C CA2589987C (fr)	2008-05-20

Family

ID=38236376

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
CA002590293A Expired - Lifetime CA2590293C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique
CA002590540A Expired - Lifetime CA2590540C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique d'une toxine botulinique pour le traitement de secretions muqueuses excessives
CA002590537A Expired - Lifetime CA2590537C (fr)	1993-12-28	1994-12-16	Utilisation de la composante neurotoxique de la toxine botulinique pour le traitement du larmoiement excessif
CA002589987A Expired - Fee Related CA2589987C (fr)	1993-12-28	1994-12-16	Methode pour traiter une secretion cholinergique influencee
CA002589989A Expired - Lifetime CA2589989C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive
CA002589968A Abandoned CA2589968A1 (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter des douleurs associees a l'activite ou la contracture musculaire

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
CA002590293A Expired - Lifetime CA2590293C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique du botulinum pour le traitement d'un muscle spastique
CA002590540A Expired - Lifetime CA2590540C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique d'une toxine botulinique pour le traitement de secretions muqueuses excessives
CA002590537A Expired - Lifetime CA2590537C (fr)	1993-12-28	1994-12-16	Utilisation de la composante neurotoxique de la toxine botulinique pour le traitement du larmoiement excessif

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CA002589989A Expired - Lifetime CA2589989C (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive
CA002589968A Abandoned CA2589968A1 (fr)	1993-12-28	1994-12-16	Utilisation du composant neurotoxique de la toxine botulinique pour traiter des douleurs associees a l'activite ou la contracture musculaire

Country Status (1)

Country	Link
CA (6)	CA2590293C (fr)

1994
- 1994-12-16 CA CA002590293A patent/CA2590293C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002590540A patent/CA2590540C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002590537A patent/CA2590537C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002589987A patent/CA2589987C/fr not_active Expired - Fee Related
- 1994-12-16 CA CA002589989A patent/CA2589989C/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002589968A patent/CA2589968A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
CA2589989A1 (fr)	1995-07-06
CA2590537C (fr)	2009-10-13
CA2590293A1 (fr)	1995-07-06
CA2590293C (fr)	2009-05-12
CA2589989C (fr)	2009-05-12
CA2589987C (fr)	2008-05-20
CA2590540C (fr)	2009-05-05
CA2589968A1 (fr)	1995-07-06
CA2590537A1 (fr)	1995-07-06
CA2590540A1 (fr)	1995-07-06

Similar Documents

Publication	Publication Date	Title
CA2180011A1 (fr)	1995-07-06	Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees
WO1995017904B1 (fr)	1995-12-07	Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees
CA2332406A1 (fr)	1994-12-22	Traitement de troubles et de maladies neuromusculaires a l'aide de differents serotypes de botulinum
CA2190011A1 (fr)	1995-11-16	Procede de reduction des maux de tete
CA2164626A1 (fr)	1994-12-22	Toxines multiples de botulinum pour le traitement des troubles neuromusculaires
EP0433299A4 (en)	1992-04-08	Treatment of gastro-intestinal disorders
EP1011695A4 (fr)	2004-05-26	Therapie a base de neurotoxines pour le traitement de troubles urologiques et de troubles connexes
EP0565616A4 (fr)	1995-01-25	Procede et dispositif amovible utilise dans le traitement auto-administre d'infections des voies urinaires et d'autres troubles en tant que bouchon urethral.
CA2164291A1 (fr)	1994-12-22	Methodes et compositions pharmaceutiques utiles pour le traitement de troubles neurologiques
IL105079A0 (en)	1993-07-08	Treatment of fibrotic disorders
CA2061665A1 (fr)	1992-08-26	Traitement de troubles des voies urinaires inferieures
CA2275167A1 (fr)	1998-06-25	Utilisation locale d'agonistes opioides kappa dans le traitement de la douleur oculaire
WO2002039999B1 (fr)	2004-04-15	Inhibition d'angiogenese du type endostatine
CA2300703A1 (fr)	1995-07-06	Methode pour traiter la sudation excessive
CA2136953A1 (fr)	1993-12-09	Methode d'utilisation d'un inhibiteur de la coagulation associe a une lipoproteine pour le traitement d'une septicemie
CA2589989A1 (fr)	1995-07-06	Utilisation du composant neurotoxique de la toxine botulinique pour traiter la sudation excessive
Firlit et al.	1975	Experience with intermittent catheterization in chronic spinal cord injury patients
WO1998001125A3 (fr)	1998-05-07	Isomeres dextrogyres d'oxybutynine et de desethyloxybutynine utilises dans le traitement de l'hyperactivite gastro-intestinale
CA2269031A1 (fr)	1998-04-23	Traitement de l'incontinence d'urine et compositions a cet usage
WO1999056767A3 (fr)	2000-03-02	Traitement d'une maladie hepatique liee a la cytokine
CA2219603A1 (fr)	1998-04-30	Methode pour stimuler la motilite gastro-intestinale grace a l'acide ellagique
WO1996029076A3 (fr)	1997-02-13	Traitement des affections instestinales inflammatoires par la cotinine
EP1712231A3 (fr)	2007-11-21	Methode d'améliorer la cinétique pharmaceutique de tipranavir

Legal Events

Date	Code	Title	Description
2007-06-07	EEER	Examination request
2015-01-27	MKLA	Lapsed	Effective date: 20141216